Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.49 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 14/20 | 0.47 |
| ▸ | MELK | Q14680 | 1/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 11/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3723069 | 0.86 | ROCK2 (0.65) | ROCK2MELKROCK1POLB | |
| SCHEMBL3713988 | 0.84 | ROCK2 (0.69) | ROCK2MELKROCK1 | |
| SCHEMBL3656437 | 0.80 | MKNK2 (0.61) | MKNK1MKNK2ROCK2MELKROCK1 | |
| SCHEMBL3801724 | 0.79 | HTT (0.54) | MKNK1MKNK2ROCK2MELKROCK1 | |
| SCHEMBL3723996 | 0.78 | ROCK2 (0.45) | ROCK2MELKROCK1 | |
| SCHEMBL3722812 | 0.78 | MELK (0.55) | MKNK1MKNK2ROCK2MELKROCK1 | |
| SCHEMBL3661410 | 0.77 | CDC7 (0.50) | MKNK1MKNK2ROCK2POLB | |
| SCHEMBL3714082 | 0.77 | ROCK2 (0.57) | MKNK1MKNK2ROCK2MELKROCK1 | |
| SCHEMBL14303253 | 0.75 | POLB (0.48) | POLB | |
| SCHEMBL3718197 | 0.74 | ROCK2 (0.57) | MKNK1MKNK2ROCK2MELKROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2234618-A1 | BENZOPYRANS AND ANALOGS AS RHO KINASE INHIBITORS | The Scripps Research Institute (US) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009079008-A1 | BENZOPYRANS AND ANALOGS AS RHO KINASE INHIBITORS | FENG YANGBO (US) | 2009-06-25 | — | — | WO | disclosed |